Cedazuridine

Phase 3Small molecule

Takeda

Cedazuridine is one of 13 small molecule programs targeting Myeloid Neoplasm. It is currently in Phase 3.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Myeloid NeoplasmRecruiting

Myeloid NeoplasmPhase 3

Recruiting

Competition

Competitive Landscape

13 competitors in Myeloid Neoplasm

#DrugCompanyPhaseTrials

Venclexta

AbbVie

Phase 3

2 2

Vidaza

KKaruna Therapeutics, Inc., a Bristol Myers Squibb company

Phase 3

2 3

Xpovio

KKaryopharm Therapeutics Inc

Phase 2

1 4

CPX-351

Jazz Pharmaceuticals

Phase 2

1 5

Dacogen

Sun Pharmaceutical Industries, Inc.

Phase 1

2 6

Jakafi

Incyte

Phase 1

1 7

ASTX030

Taiho Oncology, Inc.

Phase 3

1 8

Navitoclax

AbbVie

Phase 1

1 9

Cedazuridine

Takeda

Phase 3

1 10

Leukine

Sanofi

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q3 2027

Phase 1Active, not recruiting

Solid Tumor

NCT03875287

Q4 2028

Phase 2/3Recruiting

Myeloid Neoplasm

NCT04256317

Clinical

Trials by Indication[1]

ESS1 trial

Thorough QT Assessment of Cedazuridine in Healthy Subjects

Completed·AAstex Pharmaceuticals, Inc.·Phase 1·NCT04953923·36 enrolled

Acute Myeloid Leukemia1 trial

Decitabine and Cedazuridine in Combination With Venetoclax for the Treatment of Patients Who Have Relapsed Acute Myeloid Leukemia After Donor Stem Cell Transplant

Terminated·SSanjay Mohan·Phase 2·NCT05799079·1 enrolled

Myeloid Neoplasm1 trial

A Multi-phase Study of ASTX030 (Azacitidine and Cedazuridine) in Myeloid Neoplasm Alone or in Combination With Venetoclax in AML (AZTOUND Study)

Recruiting· Taiho Oncology, Inc. logo

Taiho Oncology, Inc.·Phase 2/3·NCT04256317·316 enrolled

Myelodysplastic Syndromes1 trial

A Study of Pevonedistat Combined With Decitabine and Cedazuridine in Adults With Higher-risk Myelodysplastic Syndromes

Withdrawn· Takeda logo

Takeda·Phase 2·NCT04985656

Solid Tumor1 trial

A Phase I Dose-Escalation Study of E7727, an Oral Cytidine Deaminase Inhibitor (CDAi) With Oral Decitabine in Subjects With Solid Tumors

Active, not recruiting·SSidney Kimmel Comprehensive Cancer Center at Johns Hopkins·Phase 1·NCT03875287·35 enrolled

Sources

References

[1]
ClinicalTrials.gov — 5 trial records for Cedazuridine. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Cedazuridine compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Cedazuridine. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Takeda company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: Takeda

Cedazuridine

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q3 2027

Q4 2028

Trials by Indication[1]

ESS1 trial

Acute Myeloid Leukemia1 trial

Myeloid Neoplasm1 trial

Myelodysplastic Syndromes1 trial

Solid Tumor1 trial

References

Drug Info

Quick Facts

Related News